Pembrolizumab Increases Response Rates but Not Survival in Resectable Locally Advanced G/GEJ Adenocarcinoma
Perioperative pembrolizumab plus chemotherapy increased pathologic complete response (pathCR) rates in resectable gastric and gastroesophageal junction (G/GEJ) adenocarcinoma, but did not achieve statistically significant improvements in event-free survival (EFS) and overall survival (OS) at final analysis of the phase 3 KEYNOTE-585 trial, results of which were published in the Journal of Clinical Oncology.